MedPath

SIGMA-TAU RESEARCH INC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:3

Trial Phases

3 Phases

Phase 1:2
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
1 (25.0%)
Phase 3
1 (25.0%)

Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Drug: ALC and Placebo
First Posted Date
2007-11-09
Last Posted Date
2012-08-28
Lead Sponsor
Sigma-Tau Research, Inc.
Target Recruit Count
27
Registration Number
NCT00555841
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)

Phase 3
Completed
Conditions
Peripheral Vascular Diseases
Intermittent Claudication
Interventions
First Posted Date
2006-11-15
Last Posted Date
2011-08-25
Lead Sponsor
Sigma-Tau Research, Inc.
Target Recruit Count
69
Registration Number
NCT00399919
Locations
🇺🇸

Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

🇺🇸

Baptist Clinical Research, Pensacola, Florida, United States

🇺🇸

Western Suburban Cardiologists, Ltd., LaGrange, Illinois, United States

and more 6 locations

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor

Phase 1
Completed
Conditions
Solid Malignancies
First Posted Date
2002-04-10
Last Posted Date
2009-06-03
Lead Sponsor
Sigma-Tau Research, Inc.
Target Recruit Count
30
Registration Number
NCT00033202
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Rhode Island Hospital, Providence, Rhode Island, United States

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.

Phase 1
Completed
Conditions
Malignant Glioma
First Posted Date
2002-04-08
Last Posted Date
2009-06-03
Lead Sponsor
Sigma-Tau Research, Inc.
Target Recruit Count
59
Registration Number
NCT00032903
Locations
🇺🇸

Rhode Island Hospital, Providence, Rhode Island, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.